Health

MS drug given green light to re-enter the market with limits

NEWS IN BRIEF — Posted April 3, 2006

Print  |   Email  |   Respond  |   Reprints  |   Like Facebook  |   Share Twitter  |   Tweet Linkedin

A Food and Drug Administration Advisory panel voted unanimously March 7 to allow the multiple sclerosis drug natalizumab, or Tysabri, to re-enter the market with restrictions on its use. The drug was withdrawn a year ago after three patients developed progressive multifocal leukoencephalopathy and two died from the brain infection.

A study published in the March 2 New England Journal of Medicine found no evidence of the serious disorder in a trial of more than 3,000 people treated with Tysabri for a range of conditions that included MS, Crohn's disease and rheumatoid arthritis.

The drug was approved November 2004 to treat relapsing-remitting MS. Studies had shown it substantially reduced the frequency of relapses.

The FDA advisory committee concluded that the drug should be made available once again. The move is unusual. The only other drug allowed back on the market after safety concerns led to its withdrawal was Lotronex.

The agency will determine what restrictions should be placed on the use of Tysabri, said Robert Temple, MD, director of FDA's office of medical policy.

The drug's manufacturers pledged to work with the FDA to finalize details of a risk management plan. They said FDA action was expected by the end of March.

Note: This item originally appeared at http://www.ama-assn.org/amednews/2006/04/03/hlbf0403.htm.

Back to top


ADVERTISEMENT

ADVERTISE HERE


Featured
Read story

Confronting bias against obese patients

Medical educators are starting to raise awareness about how weight-related stigma can impair patient-physician communication and the treatment of obesity. Read story


Read story

Goodbye

American Medical News is ceasing publication after 55 years of serving physicians by keeping them informed of their rapidly changing profession. Read story


Read story

Policing medical practice employees after work

Doctors can try to regulate staff actions outside the office, but they must watch what they try to stamp out and how they do it. Read story


Read story

Diabetes prevention: Set on a course for lifestyle change

The YMCA's evidence-based program is helping prediabetic patients eat right, get active and lose weight. Read story


Read story

Medicaid's muddled preventive care picture

The health system reform law promises no-cost coverage of a lengthy list of screenings and other prevention services, but some beneficiaries still might miss out. Read story


Read story

How to get tax breaks for your medical practice

Federal, state and local governments offer doctors incentives because practices are recognized as economic engines. But physicians must know how and where to find them. Read story


Read story

Advance pay ACOs: A down payment on Medicare's future

Accountable care organizations that pay doctors up-front bring practice improvements, but it's unclear yet if program actuaries will see a return on investment. Read story


Read story

Physician liability: Your team, your legal risk

When health care team members drop the ball, it's often doctors who end up in court. How can physicians improve such care and avoid risks? Read story

  • Stay informed
  • Twitter
  • Facebook
  • RSS
  • LinkedIn